Dear Doctor,
In preparation for the upcoming Glioma Advisory Board meeting scheduled for September 2024, we kindly request your valuable input through the following survey, which draws upon your experience at glioma centers.
This survey consists of 19 questions and is designed to take approximately 10 minutes to complete. Your insights will be instrumental in guiding our discussions and decisions regarding glioma.
Thank you for your time and contribution.
Registration
Personal information
Q3 - Which WHO classification system is used for Glioma diagnosis at your center?
*
2016 classification
2021 classification
Q4 - What is the Glioma status testing method used at your center?
*
Immunohistochemistry (IHC) alone
IHC followed by Next-Generation Sequencing (NGS)
NGS alone
Q5 - Approximately what percentage of Glioma patients have access to these tests at your center?
*
Q6 - What is the annual number of Low-Grade Glioma cases diagnosed at your center? *
Q7 - Is it possible to determine the percentage of diagnosed Glioma cases that are classified as Grade 2 or Grade 3? *
No
Yes (please specify the percentage of grade 2 patients and grade 3 patients)
Q8 - What criteria do you use to distinguish between grade 2 and grade 3 Glioma? *
Q9 - At what stages are MDT meetings conducted at your center? *
Before surgery
After surgery & before progression
Post-surgery and at disease progression
Not available
Q10 - How is the post-surgical status of the tumor (residual tumor) defined at your center?
*
Q11 - The percentage of patients achieve Gross Total Resection (GTR > 95%)....... and the percentage of residual tumors.......
*
Q12 - Based on Gross Total Resection or Subtotal Resection / Biopsy and tumor cell type Oligodendroglioma or Astrocytoma, treatment most likely to be chosen
*
Gross Total Resection
OLGIO
Grade 2
< 40 years
> 40 years
Grade 3
< 40 years
> 40 years
ASTRO
Grade 2
< 40 years
> 40 years
Grade 3
< 40 years
> 40 years
Subtotal Resection/ Biopsy
OLGIO
Grade 2
< 40 years
> 40 years
Grade 3
< 40 years
> 40 years
ASTRO
Grade 2
< 40 years
> 40 years
Grade 3
< 40 years
> 40 years
Q13 - In deciding between WW and RT/CT, does the patient’s preference matter?
*
Yes
No
Sometimes
Other (please specify)
Q14 - To what extent do you observe late adverse effects from RT/CT at your center?
*
Rare
Often
Usually
Almost always
Q15 - What are the types of late AEs? *
Q16 - What is the main reason for opting RT/CT after surgery? *
Disease recurrence
Disease transformation to a higher grade
Q17 - Who is responsible for follow-up during WW? *
Neurosurgeon
Pathologist
Radiation Oncologist
Multidisciplinary team (MDT)
Medical Oncologist
Q18 - What is the interval for imaging follow-up during WW? *
Q19 - Do you assess the tumor enhancement status during follow-up? *
